Kurtz Josef, Wekerle Thomas, Sykes Megan
Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital/Harvard Medical School, MGH East, Bldg. 149-5102 13(th) Street, Boston, MA 02129, USA.
Trends Immunol. 2004 Oct;25(10):518-23. doi: 10.1016/j.it.2004.08.007.
The establishment of mixed hematopoietic chimerism induces life-long donor-specific organ graft tolerance while obviating the need for chronic immunosuppression. Recent advances have dramatically reduced the conditioning toxicity required to achieve mixed chimerism. We argue that the achievement of high levels of donor chimerism ensures life-long deletion of donor-reactive T cells, precluding and obviating the need for regulatory mechanisms in the maintenance of tolerance. However, in situations where high levels of donor chimerism cannot be established or sustained, control of immune responsiveness can be achieved through additional mechanisms, including regulatory T cells.
混合造血嵌合体的建立可诱导终身供体特异性器官移植耐受,同时无需长期免疫抑制。最近的进展已大幅降低实现混合嵌合体所需的预处理毒性。我们认为,实现高水平的供体嵌合体可确保终身清除供体反应性T细胞,从而排除并消除维持耐受所需的调节机制。然而,在无法建立或维持高水平供体嵌合体的情况下,可通过包括调节性T细胞在内的其他机制实现免疫反应性的控制。